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compared with healthy nasal mucosa
Leonardo Balsalobre1*, Rogério Pezato1,2, Claudina Perez-Novo2, Maria Teresa S Alves3, Rodrigo P Santos1,
Claus Bachert2 and Luc LM Weckx1Abstract
Objective: To evaluate TGF-β1 expression in polypoid mucosa (epithelium and stroma) of patients with chronic
rhinosinusitis with nasal polyposis (CRSwNP).
Methods: Cross-sectional study with two groups: 17 patients with nasal polyposis and 11 controls. Polyps and
normal nasal mucosa were processed by immunohistochemical methods for TGF-β1 visualization. Then, the
percentage of TGF-β1 expression in stroma and epithelium was objectively quantified using UT Morph software.
Results: A lower percentage of positive expression was found in the epithelium of CRSwNP patients (32.44%)
versus normal controls (55.91%) (p < 0.05), and a higher percentage of positive expression in the stroma of CRSwNP
patients (23.24%) versus controls (5.88%) (p < 0.05).
Conclusion: The lower percentage of TGF-β1 expression in the nasal epithelium of CRSwNP patients may have an
impact on epithelium-directed topical treatments employed in this patient population.
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Transforming growth factor beta-1 (TGF-β1) is impli-
cated as a key protein in the tissue remodeling process.
It stimulates fibrosis (by attracting stromal cells), angio-
genesis, and accumulation of extracellular matrix [1,2].
In chronic rhinosinusitis with nasal polyposis (CRSwNP),
the remodeling process warrants a closer look, as nasal
polyp histology is characterized by diffuse mucosal edema
with a lack of extracellular matrix, unlike chronic rhino-
sinusitis without nasal polyposis (CRS) [3,4].
There is still controversy in the literature as to TGF-β1
expression in nasal polyposis. Some authors have demon-
strated higher TGF-β1 expression in patients CRSwNP
than in patients with CRS and controls [5-8], whereas
other authors have reported opposite findings, with lower
TGF-β1 expression in CRSwNP than in CRS and healthy
controls [9,10].* Correspondence: leo_balsalobre@uol.com.br
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reproduction in any medium, provided the orThere are some reasonable explanations for the dis-
crepancy found in the literature. Firstly, studies have not
discriminated between cell types for measurement, nor
have they distinguished epithelium from stroma, and,
interestingly, experiments normally use inferior turbin-
ate mucosa from healthy subjects as controls for com-
parison with sinus mucosa from CRS patients.
Another relevant potential confounding factor is the
lack of criteria for patient selection, such as no inclusion
of washout periods for corticosteroids and antibiotics, or
no assessment for atopic or asthmatic status [11,12].
The technique used to evaluate TGF-β1 expression can
also interfere with study results. We noted a trend to-
ward increased TGF-β1 expression in CRSwNP patients
when immunohistochemistry (IHC) is employed [13-16].
One factor that limits the reliability of IHC is the use
of a semi-quantitative method for evaluation, which is
thus subject to investigator bias.
The present study is novel in that we evaluated TGF-β1
expression in polyp mucosa of CRSwNP patients by strati-
fying the mucosa into epithelium and stroma groups andral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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slides. Furthermore, mucosa from the ethmoidal bulla was
used as a control.Material and methods
Patients were recruited at the Department of Otorhino-
laryngology, Federal University of São Paulo, Brazil. Sam-
ples of ethmoid bulla mucosa from patients without sinus
disease who underwent endoscopic hypophysectomy were
used as controls (n = 11). Samples from patients with adult
nasal polyposis (CRSwNP, n = 17) were obtained during
functional endoscopic sinus surgery (FESS) procedures.
The diagnosis of sinus disease was based on history, clin-
ical examination, nasal endoscopy, and computed tomog-
raphy (CT scan) of the paranasal cavities, according to
EPOS guidelines [17].
All subjects underwent a skin prick test for common in-
halant allergens (Aspergillus fumigatus, Penicillium
notatum, D. pteronyssinus, D. farina, Lolium perenne, C.
herbarum, E. mainei, T. putrescentiae, B. tropicalis, B.
kulagini, cat and dog fur) and all tests had to be negative
for the subject to be included in the experiment. Other
criteria of exclusion were a diagnosis of asthma (based on
ventilatory test), aspirin intolerance (based on history), or
cystic fibrosis.
All subjects included in the study underwent a wash-
out period of 30 days for corticosteroids and antibiotics.
The study was approved by the Research Ethics Com-
mittee of the Federal University of São Paulo, Brazil (regis-
try number 0544/09) and all participants provided written
informed consent prior to sample collection.Tissue preservation and preparation for staining
Ethmoid bulla mucosa from healthy subjects and nasal
polyp tissue from CRSwNP patients were fixated in 10%
acetaldehyde for 24 hours at room temperature immedi-
ately after surgical removal.
The specimens were preserved in 70% ethanol at 4°C,
embedded in paraffin, and cut in a microtome into
4-micron sections, which were then affixed onto Superfrost
Plus glass slides (Menzel Glaser, Braunschweig, Germany).
The slides were then dried at 60°C for a few hours.
For deparaffinization, the slides were washed successively
in xylene (3 times), 100% ethanol (3 times for 5 minutes),
and distilled water (for 5 minutes). Antigen retrieval was
done as follows: briefly, a staining dish containing citrate
buffer (pH 6.0) was pre-heated in a steamer until the
temperature reached 95–100°C. The slides were then
immersed in the staining dish. The staining dish was
cooled at room temperature. Endogenous peroxidase was
blocked with hydrogen peroxide prior to hybridization.
Sections were rinsed in distilled water and subse-
quently in PBS (pH 7.4–7.8), 2 changes, for 2 minutes.After air-drying, the sections were incubated with
mouse anti-human TGF-β1 monoclonal primary antibody
(Biosource International Inc., Camarillo, USA) and diluted
in bovine serum albumin (BSA) 1% buffer overnight.
The standard immunohistochemistry protocol was then
initiated: slides were washed in PBS and incubated with
the first reagent (KIT LSAB/DAKO, Glostrup Denmark)
for 30 minutes. The procedure was repeated once more,
with the second reagent (KIT LSAB/DAKO, Glostrup
Denmark) replacing the first one. After PBS rinsing, a DAB
reaction was carried out (0.06 g DAB, 100 mL PBS, 1 mL
H2O2) for 5 minutes and slides rinsed in running
tap water.
The slides were counterstained using Harris’ hematoxylin
solution for 3 minutes.
Finally, the slides were rinsed in running tap water,
dehydrated, cleared, and set in coverslips with resin.
Morphometric method
Microscopic examination was conducted by an investiga-
tor blinded to diagnosis. An Olympus BX51 microscope
(Shinjuku, Japan) equipped with an Oly 200 camera
(Olympus America Inc., Center Valley, USA) and a pro-
cessor (Intel Core 2 DUO, Santa Clara, USA) was used.
Images were captured using an Intel Core 2 Duo worksta-
tion, a plate reader, and UT Morph version 2.0 software,
developed by University of Texas.
Five fields per slide were examined under 400× magni-
fication, starting at the most intensely stained area and
moving in sequence to randomly selected adjacent fields.
UT Morph 2.0 software was used to quantify the per-
centage of immunostained area (Figure 1). Mucosal im-
ages were split into epithelium and stroma using Corel
Photo-Paint 9 software (Ottawa, Canada) (Figure 2).
Statistics
The data obtained were analyzed using SPSS 18 software
(IBM Corporation, NY, USA). The Kolmogorov-Smirnov
(KS) test was used to assess the normality of distribution.
Student’s t-test and the Mann-Whitney U test (for nor-
mally and non-normally distributed data respectively)
were used to test for statistically significant between-group
differences. P values of <0.05 were considered significant.
Results
Epithelium
Percent area with positive expression of TGF-β1 in the epi-
thelium is demonstrated in Table 1 (16 CRSwNP/11 con-
trols). One CRSwNP slide was excluded due to partial
damage of the epithelium; however, the stroma portion
was preserved. We found a smaller percent area of TGF-β1
expression in the epithelium of CRSwNP patients (32.44%)
as compared with controls (55.91%), p < 0.05 (Table 2).
Figure 1 Digital separation between epithelium and stroma. A) Total epithelium area (red) measured in UT Morph software. B) Area positive
for expression of TGF-β1 (red).
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Percent area with positive expression of TGF-β1 in the
stroma is demonstrated in Table 3 (17 CRSwNP/11
controls). We found a greater percent area of TGF-β1
expression in the stroma of CRSwNP patients (23.24%)
as compared with controls (5.88%), p < 0.05 (Table 4).
Discussion
TGF-β1 plays a key role in the remodeling process, con-
tributing to the interstitial matrix formation. There is dis-
crepant information on TGF-β1 expression in CRSwNP.
Some authors have reported greater expression of TGF-β1
in patients with CRSwNP as compared with healthy sub-
jects, [5-8] while other authors found the opposite [9,10].
In the present study, we demonstrated the importance
of splitting the nasal mucosa into epithelium and stroma,
because in CRSwNP, these cell subsets express TGF-β1 dif-
ferently as compared with healthy nasal mucosa.Figure 2 Assessment of TGF-b1 percentage in the epithelium. A) Histo
(TGF-β1 expression shown in brown). B) Stroma excluded and epithelium p
the non-positive area.Because of the similarities between upper and lower air-
way mucosa, some authors have compared the remodeling
process between these tissues. Bosquet et al. found a thin-
ner basement membrane with fewer elastase-positive cells
in nasal mucosa when compared to bronchial mucosa [18].
The authors also demonstrated that nasal epithelium dis-
ruption is less extensive than that observed in the lungs.
The importance of epithelial integrity and the role of
TGF-ß on the remodeling process were demonstrated by
Holgate et al., who found that epithelial injury results in
increased production and release of TGF-ß [19].
The fact that the percentage of epithelium expressing
TGF-β1 was lower in patients with CRSwNP than in
healthy subjects in our study supports the hypothesis that
the nasal mucosa may offer less resistance to edema dur-
ing the inflammatory process of nasal polyposis [4]. Ac-
cordingly, Li X et al. demonstrated decreased expression
of collagen in CRSwNP versus CRS, and suggested TGF-βlogical section (400× magnification) showing stroma and epithelium
reserved. C) Positive TGF-β1 expression in epithelium after exclusion of
Table 1 Comparison between percent area of TGF-β1
expression in the epithelium, controls versus CRSwNP
patients
Epithelium
CRSwNP Control
1 39,21% 1 41,62%
2 31,50% 2 77,41%
3 13,55% 3 46,93%
4 44,55% 4 24,38%
5 42,13% 5 62,07%
6 46,45% 6 51,53%
7 46,21% 7 47,75%
8 29,14% 8 59,70%
9 47,49% 9 82,24%
10 32,75% 10 86,01%
11 21,10% 11 35,28%
12 21,56%
13 17,14%
14 41,68%
15 15,41%
16 29.16%
Table 3 Comparison between percent area of TGF-β1
expression in the submucosa, controls versus CRSwNP
patients
Submucosa
CRSwNP Control
1 35.07% 1 20.56%
2 12.23% 2 0.00%
3 24.66% 3 0.00%
4 18.53% 4 0.00%
5 19.75% 5 10.80%
6 17.15% 6 0.00%
7 22.16% 7 0.00%
8 25.64% 8 0.00%
9 20.26% 9 15.54%
10 18.00% 10 15.77%
11 44.06% 11 0.00%
12 25.82%
13 31,50%
14 34.60%
15 13.17%
16 20.64%
17 11.87%
Table 4 Statistically significant differences in percent
area of TGF-β1 expression in the submucosa, controls
versus CRSwNP patients
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disease [3]. Van Bruaene et al. also corroborated these
findings, showing low concentrations of TGF-β1 and colla-
gen and low expression of TGF-β receptor II and receptor
III mRNA in patients with CRSwNP as compared with
controls [20].
Another factor that might contribute to different TGF-β1
expression in nasal polyps is the technique used for evalu-
ation. Methods such as ELISA or even PCR applied to
nasal tissue homogenates provide a better picture of total
load and transcription of TGF-β1 respectively. However,
they fail to localize the distribution of TGF-β1; conse-
quently, IHC is used.Table 2 Statistically significant differences in percent
area of TGF-β1 expression in the epithelium, controls
versus CRSwNP patients
Epithelium
Positive area (%)
CRSwNP Control
Mean 32.44 55.91
95% CI 32.06–38.80 42.63–69.18
Standard deviation 11.93 19.76
Minimum 13.56 24.39
Maximun 47.50 86.02
95%: CI, 95% confidence interval.
Student’s t test, p= 0.007.
Kolmogrow-Sminov test, polyposis group, p = 0.85; control group, p = 0.99.IHC has tended to show increased TGF-β in patients
with CRSwNP versus controls [3,6,16,18], but this tech-
nique is usually employed with semi-quantitative methods
for image assessment [7,13]. In our study, we used a quan-
titative method to evaluate the percentage of area stained
by TGF-β1. The weakness of this method is that it does
not allow assessment of the intensity of staining.Submucosa
Positive area (%)
CRSwNP Control
Mean 23.24 5.88
95% CI 18.69–27.79 0.1173–11.64
Standard
deviation
8.85 8.58
Minimum 11.87 0
Median 20.64 0
Maximun 44.06 22.56
Kolmogorov-
Sminov test:
p = 0.41 p = 0.0003*
Mann-Whitney.
p = 0.03*
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that could lead to erroneous interpretations, such as use
of antibiotics, anti-inflammatory or immunosuppressant
agents, as some of these drugs have shown anti-inflamma-
tory effects in the nasal mucosa [11,12]. Furthermore, fail-
ure to distinguish atopic or aspirin tolerance status during
patient selection can produce misleading results. In this
study, the minimum washout period for antibiotics and
corticosteroids was 30 days, and only patients who had
negative skin prick tests and no diagnosis of asthma
were included.
The most novel contribution of this experiment was
perhaps the use of ethmoidal mucosa from patients under-
going hypophysectomy as controls to be compared with
nasal polyp tissue. In contrast, most studies use inferior
turbinate tissue from patients undergoing rhinoplasty or
septoplasty as controls for comparison with nasal polyps
[13,15,16].
In conclusion, we found a relative decrease in percent
area of TGF-β1 expression in CRSwNP epithelium and a
relative increase in percent area of TGF-β1 expression in
the CRSwNP stroma when compared to healthy nasal
mucosa. These findings could have an impact on topical
treatments for patients with CRSwNP.
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